Seattle biotech co. to move to Houston thanks to $13.3M grant from Texas organization

CPRIT funding spotted

OncoResponse in partnership with MD Anderson Cancer Center received a portion of $73 million the Cancer Prevention and Research Institute of Texas has doled out this spring. Photo via oncoresponse.com

A biotech company has landed a more than $13 million grant from the Cancer Prevention and Research Institute of Texas.

The nearly $13.3 million grant given to OncoResponse — which is relocating from Seattle to Houston, according to CPRIT's news release — will help the company develop fully human monoclonal antibodies for treatment of cancer that otherwise would not respond to immunotherapy. OncoResponse already has a partnership with MD Anderson Cancer Center, which is one of the company’s investors.

“We are thrilled to receive this recognition from CPRIT in supporting the potential of our immunotherapy candidate OR502. We greatly appreciate the additional support from our investors as we continue to make significant progress with our drug development efforts advancing immunotherapies derived from clues of Elite Responders,” says Clifford Stocks, CEO of OncoResponse, in a news release.

Aside from the grant, OncoResponse just hauled in $14 million from existing investors in a round led by RiverVest Venture Partners. Other participants in the series D round include Venture Partners, Canaan Partners, 3B Future Health Fund, Bering Capital, Takeda Ventures, and InterVest Capital Partners.

To date, OncoResponse has raised more than $180 million, according to market research company CB Insights.

A representative of OncoResponse couldn’t be reached for comment about the company’s relocation to Houston.

MD Anderson and Seattle-based Theraclone Sciences launched OncoResponse in 2015. Rice University was among the inaugural investors.

OncoResponse’s OR2805 immunotherapy product is being evaluated in a Phase 1 clinical trial. It’s the company’s leading immunotherapy candidate. OncoResponse is also working on OR502, an antibody being prepared for investigational and clinical studies.

“The modern treatment of cancer activates the body’s own immune system to attack cancer,” OncoResponse says in a summary posted on the website of the Cancer Prevention and Research Institute of Texas (CPRIT).

“These treatments, called immunotherapy, may not be successful if the cancer can recruit bad-acting cells, such as tumor associated macrophages, or TAMs, that create barriers preventing immunotherapies from activating the body’s own defenses against the cancer. To find drugs that may help counteract these TAMs, OncoResponse looked to patients who had responded very well to immunotherapy to see if their bodies made factors to block TAMs and helped them fight their cancers.”

OncoResponse’s OR502 prevents TAMs from shutting down the body’s response to cancer, thus restoring tumor-killing immune activity, CPRIT explains.

In addition to OncoResponse, recent CPRIT grant recipients from the Houston area are:

  • Houston-based 7 Hills Pharma, $13,439,001. The company is working on immunotherapies for treatment of cancer and prevention of infectious diseases.
  • Houston-based Allterum Therapeutics, $11,721,150. The company is coming up with an antibody for treatment of patients with acute lymphoblastic leukemia. This type of cancer affects blood and bone marrow.
  • Houston-based Cell Therapy Manufacturing Center, $9.1 million. The center is a joint venture between National Resilience and MD Anderson Cancer Center that is developing cell therapy manufacturing technologies to support biotech partnerships.
  • Houston-based Pulmotect, $8,851,165. The company’s PUL-042 product is aimed at treating and preventing respiratory complications in cancer patients.
  • Cancer researcher Michael King, $6 million. The grant helped lure King to Rice from Nashville’s Vanderbilt University, where he’s been the chair of biomedical engineering. King’s lab at Vanderbilt has been testing therapies for metastatic breast cancer and prostate cancer.
  • Missouri City-based OmniNano Pharmaceuticals, $2,711,437. The pharmatech company is working on two drugs for treatment of solid tumors in patients with pancreatic cancer.

“Texas is unique because of CPRIT’s ability to invest in cutting-edge research when private capital is scarce. This is yet another way Texas is leading the nation in the fight against cancer,” Wayne Roberts, CEO of CPRIT, says in a news release.

From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

TMC Innovation announces second cohort of promising Danish health tech companies

welcome to houston

A new cohort of scientists from the Texas-Denmark BioBridge has been selected to join a Texas Medical Center Accelerator, joining forces with some of Houston’s best advisers and mentors.

This is the second year that four Danish companies have been chosen to join a special TMC Innovation Accelerator program with plans to bring their technologies to the American market. In a joint press release, the Texas Medical Center (TMC) and the BioInnovation Institute (BII), announced that the participants are scheduled to arrive in Houston on May 13 for their first session, in which they’ll work on US customer validation. After that, they’ll take part in the full program, which will allow the founders to make their plans for strategic development over the course of six months.

Just as the TMC Innovation Factory offers help for founders who have set their sights on success in the US market, the Danish BioInnovation Institute provides life science startups with the connections, infrastructure and financial support necessary to bring their ideas to the public.

The companies selected include:

  • Alba Health is pioneering a gut microbiome test for young children that’s informed by AI.
  • AMPA Medical has created InterPoc, a more discrete alternative to types of stoma bags currently available for ileostomy patients.
  • Droplet IV is a medical device that automatically flushes IV lines, reducing waste and making nurses’ jobs easier.
  • Metsystem is a cancer metastasis platform aimed at predicting what the most effective cancer drug is for each patient.

“We are excited to welcome these startups to TMC as Danish companies are making significant strides in drug discovery and health tech developments” says Devin Dunn, head of the accelerator for Health Tech, in the release. “As they look to expand into the US market, the collaborative environment fostered by our dedicated team, programs, and clinical community will help them advance their innovations, foster research collaborations, and further develop their technologies here in Houston.”

The program for the accelerator is based on the successes of the TMC Innovation (TMCi) Health Tech Accelerator program. The TMC Denmark BioBridge was established in 2019 as a collaboration between TMC and the Ministry of Foreign Affairs of Denmark.

Houston hospital flies in drone delivery service for medical supplies, prescriptions

incoming

A Houston hospital system has announced that it has plans to launch a drone delivery service for specialty prescriptions and medical supplies in 2026.

Memorial Hermann Health System announced that it intends to be the first health care provider in Houston to roll out drone delivery services from San Francisco-based Zipline, a venture capital-backed tech company founded in 2014 that's completed 1 million drone deliveries.

"As a system, we are continuously seeking ways to improve the patient experience and bring greater health and value to the communities we serve. Zipline provides an innovative solution to helping our patients access the medications they need, quickly and conveniently, at no added cost to them," Alec King, executive vice president and CFO for Memorial Hermann, says in a news release.

Zipline boasts of achieving delivery times seven times faster than traditional car deliveries and can usually drop off packages at a rate of a mile a minute. The drones, called Zips, can navigate any weather conditions and complete their missions with zero emissions.

Per the release, the service will be used to deliver items to patients or supplies or samples between its locations.

"Completing more than one million commercial deliveries has shown us that when you improve health care logistics, you improve every level of the patient experience. It means people get better, faster, more convenient care, even from the comfort of their own home," adds Keller Rinaudo Cliffton, co-founder and CEO of Zipline. "Innovators like Memorial Hermann are leading the way to bring better care to the U.S., and it's going to happen much faster than you might expect."

Houston tech founder shines spotlight on small businesses with new awards initiative

houston innovators podcast episode 234

For decades, small businesses have operated in essentially the same manner — handwritten notes to request time off, manual punch cards to clock in, and verbal agreements to swap shifts. And 10 years ago, Houstonian Rushi Patel thought it was time to upgrade these local shops, eateries, and other businesses.

Homebase, which was founded in San Francisco in 2014 and has its largest office in Houston, provides a suite of software tools for employee scheduling, time tracking, communication, and task management for its users, most of which are small businesses.

After a decade of growing its technology and clientbase, Patel, co-founder and COO of the company, explains the unique challenges these small businesses face on the Houston Innovators Podcast — as well as how Homebase helps.

"It's a bit of an orchestra in terms of what entrepreneurs have to do. Your job is to compose a little, but conduct as well," Patel says on the show. "You've built the song of what you want to have happen, but you're conducting lots of different things to make it a reality as a small business owner."



Patel explains how optimizing these personnel aspects of the business frees up founders and managers and improves the employee experience too. Currently, the job market is competitive for these types of businesses, and retention and hiring are major focus points for entrepreneurs.

With 10 years of data and experience of working with small businesses, Homebase introduced a new awards program this week in honor of National Small Business Week. The inaugural Top Local Workplace Awards honored over 50,000 businesses across the country for a range of positive workplace factors — like pay transparency and employee engagement.

"There are over 2 million employee-centric, main street type of businesses in the United States," Patel says, "these are the restaurants, the retailers, and the service providers. They employ north of 70 million people, so there's a lot of impact that these businesses can have. But what we found was they deserve recognition, and there wasn't recognition for the good practices that these employers were doing."

Using its data, which includes over 2.5 million hourly worker data points, Homebase's team implemented the awards to highlight the companies providing their employees — who are in most cases considered a work family, as Patel says — with a great experience.

View All Listings